June 16, 2020 / 3:15 PM / 17 days ago

Britain's drug regulator suspends hydroxychloroquine trial recruitment

FILE PHOTO: The drug hydroxychloroquine, pushed by U.S. President Donald Trump and others in recent months as a possible treatment to people infected with the coronavirus disease (COVID-19), is displayed at the Rock Canyon Pharmacy in Provo, Utah, U.S. May 27, 2020. REUTERS/George Frey/File Photo

LONDON (Reuters) - Britain’s drug regulator on Tuesday instructed scientists trialling the use of malaria drug hydroxychloroquine for the treatment or prevention of COVID-19 to suspend the recruitment of participants.

The Medicines and Healthcare products Regulatory Agency (MHRA) said it was following “emerging concerns” about the use of the drug, and also cited a UK trial which found no meaningful mortality benefit in patients hospitalised with COVID-19.

Reporting by Alistair Smout, editing by Estelle Shirbon

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below